title: A role for neuropeptide Y Y5 but not the Y1-receptor subtype in food deprivation-induced reinstatement of heroin seeking in the rat.
abstract: OBJECTIVE
  Neuropeptide Y (NPY), an orexigenic peptide that is released during periods of food restriction, has been shown to have a significant modulatory impact on drug-related behaviors. We have previously reported that both acute food deprivation (FD) and NPY injections can reinstate extinguished drug-seeking behavior, a proposed animal model of relapse to drug abuse. However, it is not clear whether the FD effect on drug seeking is dependent on NPY transmission. Here, we used the reinstatement model to assess the role of NPY Y1 and Y5-receptor-mediated transmission in FD-induced reinstatement of heroin seeking.
  
  
  METHODS
  Rats were trained to self-administer heroin for 10-12 days (0.1 mg/kg/infusion/intravenous). Animals then underwent extinction training followed by drug-seeking reinstatement tests under 21 h of FD and sated conditions.
  
  
  RESULTS
  Injections of a novel NPY Y5-receptor antagonist, Lu AA33810 (0.0, 1.0, or 30.0 mg/kg/IP), resulted in a significant attenuation of FD-induced reinstatement of extinguished heroin seeking. However, no significant effects on reinstatement were found for the Y1-receptor antagonist, BIBO 3304 (0.0, 5.0, or 10.0 nmol/intracerebroventricular).
  
  
  CONCLUSIONS
  These results suggest that while signals mediated through NPY Y1 receptors play a modest role in reinstatement, activation of Y5 receptors has a critical function in FD-induced reinstatement of heroin-seeking behavior.
authors.affiliation: Department of Psychology, Center for Studies in Behavioral Neurobiology/Groupe de Recherche en Neurobiologie Comportementale, Concordia University, 7141 Sherbrooke St. W, Montreal, QC, H4B 1R6, Canada.
authors.forename: Tia
authors.initials: T
authors.lastname: Maric
authors.forename: Firas
authors.initials: F
authors.lastname: Sedki
authors.forename: Danielle
authors.initials: D
authors.lastname: Chafetz
authors.forename: Nick
authors.initials: N
authors.lastname: Schoela
authors.forename: Uri
authors.initials: U
authors.lastname: Shalev
mesh_terms: D000818:Animals; D001120:Arginine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D001582:Benzothiepins / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005508:Food Deprivation; D003932:Heroin / Q000008:administration & dosage*; D008297:Male; D051381:Rats; D020318:Rats, Long-Evans; D017476:Receptors, Neuropeptide Y / Q000187:drug effects / Q000378:metabolism*; D012008:Recurrence; D012646:Self Administration; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D001582:Benzothiepins; C539254:N-((4-((4,5-dihydro(1)benzothiepino(5,4-d)thiazol-2-yl)amino)cyclohexyl)methyl)methanesulfonamide; D017476:Receptors, Neuropeptide Y; D013449:Sulfonamides; C097212:neuropeptide Y-Y1 receptor; C100568:neuropeptide Y5 receptor; D003932:Heroin; D001120:Arginine; C117416:BIBO 3304